Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance of [14C]-D-0502 in healthy women
NCT05339633Phase 1Completed
- Sponsor
- InventisBio
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taragarestrant in estrogen receptor-positive breast cancer (ER+), sponsored by InventisBio. Primary endpoint: Radiolabel recovery at 14 days. Started Mar 2022; status: completed.
02
Drugs
taragarestrant
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT05339633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339633.